These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 18774442)

  • 1. Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson's disease.
    Setter SM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S45-63, vi. PubMed ID: 18774442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug therapies for Parkinson's disease: A database analysis of patient compliance and persistence.
    Tarrants ML; Denarié MF; Castelli-Haley J; Millard J; Zhang D
    Am J Geriatr Pharmacother; 2010 Aug; 8(4):374-83. PubMed ID: 20869623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apomorphine for the acute treatment of "off" episodes in Parkinson's disease.
    Stacy M; Silver D
    Parkinsonism Relat Disord; 2008; 14(2):85-92. PubMed ID: 18083605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of early Parkinson's disease. Part 1.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):193-205. PubMed ID: 19176960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An artist's view of drug-induced hallucinosis.
    Ebersbach G
    Mov Disord; 2003 Jul; 18(7):833-4. PubMed ID: 12815666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A drug holiday in the treatment of Parkinson's disease].
    van Manen J
    Ned Tijdschr Geneeskd; 1986 May; 130(20):899-902. PubMed ID: 3724863
    [No Abstract]   [Full Text] [Related]  

  • 7. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease.
    Grosset KA; Reid JL; Grosset DG
    Mov Disord; 2005 Nov; 20(11):1397-404. PubMed ID: 16092116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients.
    Papapetropoulos S; Argyriou AA
    Parkinsonism Relat Disord; 2005 Jun; 11(4):265-6; author reply 267. PubMed ID: 15878591
    [No Abstract]   [Full Text] [Related]  

  • 9. Zonisamide for the treatment of Parkinson's disease.
    Miwa H
    Expert Rev Neurother; 2007 Sep; 7(9):1077-83. PubMed ID: 17868006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intervening in the neuropsychiatric features of Parkinson's disease.
    Weintraub D; Stern MB
    Expert Rev Neurother; 2007 Jun; 7(6):699-710. PubMed ID: 17563252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Insufficient medication compliance in Parkinson's disease].
    Aerts MB; van der Eijk M; Kramers K; Bloem BR
    Ned Tijdschr Geneeskd; 2011; 155():A3031. PubMed ID: 21527053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D; Oliver-Willwong R
    Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parkinson's disease--Part 2: Treatment of motor symptoms.
    Weintraub D; Comella CL; Horn S
    Am J Manag Care; 2008 Mar; 14(2 Suppl):S49-58. PubMed ID: 18402508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suboptimal medication adherence in Parkinson's disease.
    Grosset KA; Bone I; Grosset DG
    Mov Disord; 2005 Nov; 20(11):1502-7. PubMed ID: 16037924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: the ROPI-PARK study.
    Valldeoriola F; Cobaleda S; Lahuerta J
    Clin Neurol Neurosurg; 2009 Nov; 111(9):742-7. PubMed ID: 19733003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pill counts, self reports, and electronic monitoring -- which is most informative in the study of therapy adherence in Parkinson's disease?
    Grosset K; Grosset D
    Mov Disord; 2007 Nov; 22(15):2294. PubMed ID: 17724748
    [No Abstract]   [Full Text] [Related]  

  • 17. Optimizing bioavailability in the treatment of Parkinson's disease.
    Seeberger LC; Hauser RA
    Neuropharmacology; 2007 Dec; 53(7):791-800. PubMed ID: 17936857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing medications in Parkinson's disease (PD) patients during acute admissions to a District General Hospital.
    Magdalinou KN; Martin A; Kessel B
    Parkinsonism Relat Disord; 2007 Dec; 13(8):539-40. PubMed ID: 17241810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When a Parkinson's disease patient starts to hallucinate.
    Poewe W
    Pract Neurol; 2008 Aug; 8(4):238-41. PubMed ID: 18644910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
    Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
    Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.